Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus olaparib versus durvalumab plus placebo in cisplatin-ineligible unresectable stage IV urothelial cancer
2017-004556-27Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in transitional cell carcinoma (TCC) and bladder cancer comparing Durvalumab plus olaparib with Durvalumab plus placebo (2 arms). Primary endpoint: Progression-free survival. Started Mar 2018; status: completed.
02
Drugs
durvalumabolaparib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2017-004556-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004556-27.